Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention which are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction.
LMWHs are However, it is associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin (UFH), for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane.
Get Sample copy of this Report @: https://www.theresearchinsights.com/request_sample.php?id=7309
In terms of approved indication, the market is divided into prophylaxis in hip replacement surgery, prophylaxis in knee replacement surgery, prophylaxis in abdominal surgery, prophylaxis in acutely ill medical patients, secondary prophylaxis or extended treatment in cancer patients, inpatient treatment of deep vein thrombosis without pulmonary embolism, outpatient treatment of deep vein thrombosis with or without pulmonary embolism, unstable angina and non-ST elevated MI, and acute ST-elevation MI. In terms of end-user, the market is segmented into hospitals, nursing homes & private clinics, assisted living facilities & long-term care institutions, and home health care.
Key players operating in the global low molecular weight heparin market include Sanofi S.A., Pfizer, Inc., LEO Pharma A/S, and Novartis AG
This report provides an effective business outlook, different case studies from various top-level industry experts, business owners, and policymakers have been included to get a clear vision about business methodologies to the readers. SWOT and Porter’s Five model have been used for analyzing the Low-Molecular-Weight Heparin (LMWH)market on the basis of strengths, challenges and global opportunities in front of the businesses.
Get up to 20% Discount on this Report @:
In the last section of the report, it offers informative data of different manufacturers responsible for the growth of the market. For a better understanding of the market, this research study has been presented by using graphical presentation techniques like chart, graphs, tables, and pictures. It will help to both existing players as well as new entrants in the market.
The key questions answered through this research report:
- Who are the target clients of global Low-Molecular-Weight Heparin (LMWH)market?
- Which sales strategies are useful for increasing the sale worldwide?
- What are the challenges, risks, and threats faced by businesses?
- What is the pricing structure across several regions?
- Who are the major key players in the global market?
- How much is the size of the global Low-Molecular-Weight Heparin (LMWH)market?
- What are the internal and external drivers and restraining factors of the global Low-Molecular-Weight Heparin (LMWH)market?
For More Information:
Table of Contents:
Global Low-Molecular-Weight Heparin (LMWH)Market Research Report
Chapter 1 Low-Molecular-Weight Heparin (LMWH) Market Overview
Chapter 2 Global Economic Impact on Industry
Chapter 3 Global Market Competition by Manufacturers
Chapter 4 Global Production, Revenue (Value) by Region
Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions
Chapter 6 Global Production, Revenue (Value), Price Trend by Type
Chapter 7 Global Market Analysis by Application
Chapter 8 Manufacturing Cost Analysis
…….CONTINUED FOR TOC